Abstract:Genome-wide associations studies (GWAS) have identified >400 loci associated with common human diseases. Despite the extraordinary achievement that these results represent, several questions remain unanswered: (i) What is the contribution of rare variants to common diseases not addressed by GWAS? (ii) What are the functional variants underlying the GWAS associations? To answer these questions, we first explored the role of common and rare variants in morbid obesity (BMI>40) by identifying all the variants in the intervals of two endocannabinoid metabolic genes (MGLL and FAAH) using targeted sequencing. We used two different statistical approaches (single marker tests and collapsed markers tests) to identify variants in four intervals associated with high BMI. The majority of the associated variants are located in promoter sequences or in predicted transcriptional enhancers, suggesting their regulatory role. Additionally, we demonstrate that the set of rare variants in the FAAH promoter associated with BMI are also associated with an increased level of anandamide, a FAAH substrate, further suggesting a functional role in obesity. In a second study, we examined one of the most compelling GWAS that had identified SNPs in the 9p21 gene desert associated with coronary artery disease (CAD) and Type 2 diabetes (T2D). We identified 33 enhancers in 9p21; the interval is the second most dense gene-desert for predicted enhancers and is six times denser than the whole genome. The activity of three of these enhancers is affected by regulatory variants that show allelic differences in DNA-protein affinity and are strongly associated with either CAD or T2D. Some of these variants are predicted to disrupt the transcription-binding site relevant to CAD biology. Our study shows that the 9p21 gene desert is significantly enriched in enhancer elements and suggests the associations with CAD and T2D likely result from the cumulative contributions of multiple regulatory variants. Taken together, our studies show that a comprehensive approach of human genetics that integrates rare variants and functional knowledge, such as regulatory elements or metabolic and cell-specific effects, can leverage the findings of GWAS and lead to a deeper functional understanding of the role of genetic variation in human diseases.

Genetic associations of protein-coding variants in human disease

Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes

Rare variant contribution to human disease in 281,104 UK Biobank exomes

Exome sequencing and analysis of 454,787 UK Biobank participants

Deciphering the genetic basis of common diseases by integrated functional annotation of common and rare variants

Rare coding variant analysis for human diseases across biobanks and ancestries

Meta-Analysis of Gene Level Association Tests

Large-scale whole-exome sequencing of neuropsychiatric diseases and traits in 350,770 adults

Protein-altering variants at copy number-variable regions influence diverse human phenotypes

Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases

Meta-analysis of Gene-Level Tests for Rare Variant Association.

Rare variant associations with plasma protein levels in the UK Biobank

Analysis of protein-coding genetic variation in 60,706 humans

Identifying Disease Associations Via Genome-Wide Association Studies

Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk

Identifying novel genetic and phenotypic associations to genomic features by leveraging off-target reads in exome sequencing data

A Large-Scale Exome-Wide Association Study Identifies Novel Germline Mutations in Lung Cancer

Potential etiologic and functional implications of genome-wide association loci for human diseases and traits

Analysis of rare genetic variation underlying cardiometabolic diseases and traits among 200,000 individuals in the UK Biobank

A global atlas of genetic associations of 220 deep phenotypes

Exome sequencing identifies novel susceptibility genes and defines the contribution of coding variants to breast cancer risk.